Sitagliptin
Who holds supplier records for Sitagliptin? 7 organisations hold a current record for Sitagliptin: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (5), Netherlands (1) and China (1).
Most records are filed under another form of this substance: Sitagliptin Phosphate (55 current sources). A DMF or CEP is listed under the form it names.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Sitagliptin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/sitagliptin
Reading the evidence
- 7 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
5 of the 7 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 4 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Sitagliptin expires 25 Feb 2035. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (7)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Sitagliptin. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Biocon LimitedIndiaActive DMF 36558, 37684 · latest filing Mar 2024
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 34400 · latest filing Dec 2019
- HIKAL LTDIndia Company GMP cert on recordActive DMF 37288 · latest filing Jun 2022
- MOREPEN LABORATORIES LTDIndia Company GMP cert on recordActive DMF 35524 · latest filing Dec 2020
- TAPI NL BVNetherlandsActive DMF 33428 · latest filing Jan 2019
- Zhejiang Jingsheng Pharmaceutical Co., Ltd.ChinaActive DMF 39440 · latest filing Jan 2024
- Zydus Lifesciences LimitedIndia Company GMP cert on recordActive DMF 43898 · latest filing Mar 2026
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (15 listed products contain Sitagliptin). The latest listed patent expires 25 Feb 2035. The latest listed exclusivity runs to 24 Nov 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used as an oral antihyperglycemic agent for the treatment of type 2 diabetes. It works by increasing incretin levels, which inhibit glucagon release, thereby increasing insulin secretion.
Chemical identity
- IUPAC name
- (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
- Canonical SMILES
- C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
- InChIKey
- MFFMDFFZMYYVKS-SECBINFHSA-N
- Synonyms
- lez-763, lez763, zituvimet component sitagliptin, zituvio
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Dipeptidyl Peptidase 4 Inhibitor
- Mechanism of action
- Dipeptidyl Peptidase 4 Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Sitagliptin?
7 organisations hold an active US FDA Type II Drug Master File or a CEP for Sitagliptin: Biocon Limited (India), Dr. Reddy's Laboratories Ltd. (India), HIKAL LTD (India), MOREPEN LABORATORIES LTD (India), TAPI NL BV (Netherlands), Zhejiang Jingsheng Pharmaceutical Co., Ltd. (China) and Zydus Lifesciences Limited (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Sitagliptin Drug Master Files are active?
Biocon Limited (DMF 36558, 37684), Dr. Reddy's Laboratories Ltd. (DMF 34400), HIKAL LTD (DMF 37288), MOREPEN LABORATORIES LTD (DMF 35524), TAPI NL BV (DMF 33428), Zhejiang Jingsheng Pharmaceutical Co., Ltd. (DMF 39440) and Zydus Lifesciences Limited (DMF 43898). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Sitagliptin?
Yes. The latest patent listed for an approved US product containing Sitagliptin expires 25 Feb 2035, across 15 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Sitagliptin supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Sitagliptin?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.